Loading...
•
Dec 31, 2020
Amgen Q4 2020 Earnings Report
Amgen reported a 7% increase in total revenue, driven by higher volume growth, but faced a decrease in GAAP EPS due to amortization of costs associated with the Otezla acquisition.
Key Takeaways
Amgen's Q4 2020 financial results showed a 7% increase in total revenues to $6.6 billion, driven by volume growth. However, GAAP EPS decreased by 3% to $2.76, primarily due to Otezla acquisition costs. Non-GAAP EPS increased by 5% to $3.81. The company's 2021 revenue guidance is $25.8-$26.6 billion.
Total revenues increased by 7% to $6.6 billion, driven by higher volume growth.
GAAP EPS decreased by 3% to $2.76, impacted by Otezla acquisition amortization.
Non-GAAP EPS increased by 5% to $3.81, driven by increased revenues.
Product sales increased 8% globally, driven by 13% volume growth across the portfolio.
Amgen
Amgen
Amgen Revenue by Segment
Revenue by Segment
Repatha Revenue
CapyFin.comEVENITY Revenue
CapyFin.comProlia Revenue
CapyFin.comOtezla Revenue
CapyFin.comEnbrel Revenue
CapyFin.comKyprolis Revenue
CapyFin.comXGEVA Revenue
CapyFin.comVectibix Revenue
CapyFin.comNplate Revenue
CapyFin.comBLINCYTO Revenue
CapyFin.comAranesp Revenue
CapyFin.comParsabiv Revenue
CapyFin.comAMJEVITA / AMGEVITA Revenue
CapyFin.comMVASI Revenue
CapyFin.comNeulasta Revenue
CapyFin.comOther products Revenue
CapyFin.com Forward Guidance
Amgen anticipates total revenues between $25.8 billion and $26.6 billion for 2021. The company projects GAAP EPS to be in the range of $12.12 to $13.17 and non-GAAP EPS in the range of $16.00 to $17.00.
Positive Outlook
- Total revenues in the range of $25.8 billion to $26.6 billion.
- GAAP EPS in the range of $12.12 to $13.17.
- Non-GAAP EPS in the range of $16.00 to $17.00.
- Capital expenditures to be approximately $900 million.
- Share repurchases in the range of $3.0B to $4.0B subject to our Board's authorization.
Revenue & Expenses
Visualization of income flow from segment revenue to net income